Prognosis in Women with Breast Cancer and Private Extra Insurance Coverage

[1] Pestalozzi B(2009)Survival of cancer patients in Europe, 1995–2002: the EUROCARE 4 study. Edited by Riccardo Capocaccia et al Eur J Cancer. 45 901-1094

[2] Castiglione M(2008)Primary breast cancer: ESMO clinical recommentations for diagnosis, treatment and follow-up Ann Oncol 19 ii7-ii9

[3] Piñero A(2007)Consensus meeting on sentinel lymph node biopsy in breast cancer. Spanish society of mastology and breast disease Cir Esp 82 146-149

[4] Giménez J(2003)Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833-842

[5] Merck B(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet. 365 1687-717

[6] Martin M(2004)Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study J Clin Oncol 22 2587-2593

[7] Villar A(2005)Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302-2313

[8] Sole-Calvo A(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 2 1431-1439

[9] Alba E(1999)Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1993-2000

[10] Martín M(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092

[1] Pestalozzi B(2009)Survival of cancer patients in Europe, 1995–2002: the EUROCARE 4 study. Edited by Riccardo Capocaccia et al Eur J Cancer. 45 901-1094

[2] Castiglione M(2008)Primary breast cancer: ESMO clinical recommentations for diagnosis, treatment and follow-up Ann Oncol 19 ii7-ii9

[3] Piñero A(2007)Consensus meeting on sentinel lymph node biopsy in breast cancer. Spanish society of mastology and breast disease Cir Esp 82 146-149

[4] Giménez J(2003)Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833-842

[5] Merck B(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet. 365 1687-717

[6] Martin M(2004)Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study J Clin Oncol 22 2587-2593

[7] Villar A(2005)Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302-2313

[8] Sole-Calvo A(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 2 1431-1439

[9] Alba E(1999)Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1993-2000

[10] Martín M(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092